Roles and Mechanisms of Herbal Medicine for Diabetic Cardiomyopathy: Current Status and Perspective.
Jinfan TianYingke ZhaoYanfei LiuYue LiuKeji ChenShuzheng LyuPublished in: Oxidative medicine and cellular longevity (2017)
Diabetic cardiomyopathy is one of the major complications among patients with diabetes mellitus. Diabetic cardiomyopathy (DCM) is featured by left ventricular hypertrophy, myocardial fibrosis, and damaged left ventricular systolic and diastolic functions. The pathophysiological mechanisms include metabolic-altered substrate metabolism, dysfunction of microvascular, renin-angiotensin-aldosterone system (RAAS) activation, oxidative stress, cardiomyocyte apoptosis, mitochondrial dysfunction, and impaired Ca2+ handling. An array of molecules and signaling pathways such as p38 mitogen-activated protein kinase (p38 MAPK), c-Jun N-terminal kinase (JNK), and extracellular-regulated protein kinases (ERK) take roles in the pathogenesis of DCM. Currently, there was no remarkable effect in the treatment of DCM with application of single Western medicine. The myocardial protection actions of herbs have been gearing much attention. We present a review of the progress research of herbal medicine as a potential therapy for diabetic cardiomyopathy and the underlying mechanisms.
Keyphrases
- left ventricular
- heart failure
- oxidative stress
- signaling pathway
- type diabetes
- hypertrophic cardiomyopathy
- wound healing
- cardiac resynchronization therapy
- acute myocardial infarction
- left atrial
- mitral valve
- aortic stenosis
- current status
- angiotensin ii
- blood pressure
- cell death
- angiotensin converting enzyme
- protein kinase
- induced apoptosis
- ischemia reperfusion injury
- transcription factor
- south africa
- pi k akt
- working memory
- tyrosine kinase
- cell proliferation
- dna damage
- risk assessment
- high resolution
- endoplasmic reticulum stress
- coronary artery disease
- atrial fibrillation
- transcatheter aortic valve replacement
- insulin resistance
- climate change
- aortic valve
- percutaneous coronary intervention
- single cell